Mentions
Extended reach
Total likes
Video views
AI synopsis
The discussion highlights the recent NEJM publication, with several posts emphasizing the study’s null results, such as 'no significant reduction in stroke,' using words like 'challenge' and 'no benefit' to reflect critical engagement. Words like 'must read' and references to specific statistics demonstrate high interest and deep engagement, though the overall implication for practice is moderate rather than transformative.
Most discussions acknowledge the study's results showing no significant benefit from anticoagulation in patients with high-rate episodes, indicating general consensus or cautious agreement.
The discussions display high interest, citing recent trials, detailed data, and implications for clinical practice, suggesting strong engagement with the topic.
Multiple comments analyze trial outcomes, reference specific statistics, and debate clinical implications, showing deep engagement.
While the results challenge previous assumptions about anticoagulation efficacy in AHREs, the overall impact appears moderate, impacting ongoing debate more than immediate practice change.
Oral anticoagulants reduce the risk of stroke in patients with atrial fibrillation. Implantable cardiac devices can detect subclinical atrial high-rate episodes in patients without #AFib. Full NOAH-AFNET 6 trial Research Summary: https://t.co/e45Il0OeG2 #AFibAwarenessMonth
Anticoagulation with #Edoxaban in Patients with #AF Atrial High-Rate Episodes. #AHA23 #DOAC https://t.co/OsTfyOpYpN
Tienes un paciente de 80 años con marcapasos. De repente encuentras una racha de fibrilación auricular en la revisión, de 15 minutos de duración. Anticoagulantes? Anticoagulation with Edoxaban in Patients with Atrial High-Rate Episodes | NEJM https://t.co/tL0Y0sm7gR
Original Article: Anticoagulation with Edoxaban in Patients with Atrial High-Rate Episodes (NOAH-AFNET 6 trial) https://t.co/e45Il0OeG2 Editorial: Harnessing the Deluge of Rhythm-Monitoring Data for the Prevention of Stroke https://t.co/MspuxG7c40 https://t.co/ioe6wI3jWJ
Anticoagulation with Edoxaban in Patients with Atrial High-Rate Episodes | NEJM https://t.co/1oYkAuvwMX https://t.co/mGp1URNUab
Reconciling favorable results in ARTESIA with neutral or harmful results in NOAH-AFNET 6 (edoxaban vs placebo) is challenging! https://t.co/wJjM2Apzp2 High Rx discontinuation rate: 58-59% (24% for AF>24h) PEP (OT analysis): 0.71 vs 1.29% /PY, HR 0.55, 0.37-0.83
This week’s podcast discusses the KETOCTA study and stroke prevention in patients with device-detected atrial fibrillation. Key findings from two significant trials highlight the effectiveness of direct oral…
Dr Sander van Doorn and Dr Christian Ruff discuss current and future treatment options for stroke prevention in atrial fibrillation patients, focusing on FRAILAF and AZALEA studies exploring anticoagulation therapies…
Providing full prescription coverage after a myocardial infarction increased medication adherence slightly and reduced major vascular events and revascularization rates without raising healthcare costs.
Silent cerebral embolism and antithrombotic strategies in patients with AF and CAD are the focus of this podcast featuring John Mandrola MD. Explore the implications of recent studies on stroke prevention and management…
This week's podcast covers SCAF clues, DOAC reversal trial findings, stroke therapy trials, and changes in observational studies and blood pressure management in stroke care. The discussion provides insights into recent…
This week, John Mandrola MD discusses the implications of left atrial appendage occlusion (LAAO) during cardiac surgery for stroke prevention in atrial fibrillation. Evidence indicates a significant reduction in stroke…
This week’s podcast reviews significant trials including NOAH-AFNET 6 and ARTESiA that highlight the role of direct oral anticoagulants (DOACs) in preventing ischemic stroke among patients with device-detected atrial…
Happy Birthday, TIMI! Four decade of gigantic science! https://t.co/uDvmtC8Mjm It was a pleasure to host TIMI's Founding Father - Dr. Braunwald - and today's haed of TIMI Genetics Core Laboratory - Dr. Ruff - at HOMe! https://t.co/2w4yjyFKuw https://t.co/HcuSTgKjaq https://t.co/etRYas7izr
@Mel_Gunawardene @EHRAPresident @arbelo_e NOAH-AF-NET https://t.co/1VC5pjGT0k ARTESiA https://t.co/mRmdJWh0qV #EHRAchat https://t.co/SWqFZaCoqH
@towa2405 6分程度でも塞栓症のリスクは上がると考えられています。ただ、DOACを導入してみたらどうかということについてはNOAH-AFNET6、ARTESIAという試験でbenefitを示せませんでした。CHADS 0点の臨床的に診断されたAFにDOACを導入するか、に似ています。 https://t.co/iMHDAd9RaT https://t.co/P9dVPGWx0C
RT @afnet_ev: @emilycob @JAHA_AHA @JimSiegler 2. There were more major bleedings or deaths with edoxaban, and edoxaban did not significantl…
@emilycob @JAHA_AHA @JimSiegler 2. There were more major bleedings or deaths with edoxaban, and edoxaban did not significantly reduce the low rate of stroke (HR 0.8). DOI: 10.1056/NEJMoa2303062 5/5
RT @gunnar_heine: "Sometimes the old ways are best"? Dr. Sander van Doorn's FRAIL-AF study with @AntMarlies @stephanschirmer1 @dgfn @oegnep…
"Flowering News" Dr. Christian Ruff's AZALEA Study with @AntMarlies @stephanschirmer1 @dgfn @oegnephro https://t.co/UpW6CrMFNI @bbikdeli @delphinedouill5 @isabellemahe1 @floriancustodis @LaurentBertole1 @winkeldoc @nervensystemck @lastwalsh @JaninePoss https://t.co/xO2WMurArw
"Sometimes the old ways are best"? Dr. Sander van Doorn's FRAIL-AF study with @AntMarlies @stephanschirmer1 @dgfn @oegnephro https://t.co/zzjKMlMzgw @bbikdeli @delphinedouill5 @isabellemahe1 @floriancustodis @LaurentBertole1 https://t.co/XH1KEbdQHL
On your Way to #ACC2024 ? Here come 2 landmark studies from #ESC2023 and #AHA2023 : FRAIL-AF with Sander van Doorn & AZELEA with Christian Ruff @StephanSchirme1 @AntMarlies @oegnephro @com_SFNDT @dgfn_ev @YoungDgk @isth @IsthPresident https://t.co/7lsGBqWb4r via @YouTube
RT @StrokeAHA_ASA: ICYMI: To Anticoagulate or Not to Anticoagulate https://t.co/3xU26liwYM In this #BloggingStroke post, @MaryamZulfiqar_…
RT @StrokeAHA_ASA: ICYMI: To Anticoagulate or Not to Anticoagulate https://t.co/3xU26liwYM In this #BloggingStroke post, @MaryamZulfiqar_…
RT @MaryamZulfiqar_: Lets discuss Anticoagulation with Edoxaban in Patients with Atrial High-Rate Episodes @StrokeAHA_ASA
RT @StrokeAHA_ASA: ICYMI: To Anticoagulate or Not to Anticoagulate https://t.co/3xU26liwYM In this #BloggingStroke post, @MaryamZulfiqar_…
Lets discuss Anticoagulation with Edoxaban in Patients with Atrial High-Rate Episodes @StrokeAHA_ASA https://t.co/dgCqpDn0lL
RT @StrokeAHA_ASA: ICYMI: To Anticoagulate or Not to Anticoagulate https://t.co/3xU26liwYM In this #BloggingStroke post, @MaryamZulfiqar_…
ICYMI: To Anticoagulate or Not to Anticoagulate https://t.co/3xU26liwYM In this #BloggingStroke post, @MaryamZulfiqar_ discusses @NEJM article "Anticoagulation with Edoxaban in Patients with Atrial High-Rate Episodes" by Kirchhof et al.
@ecgandrhythmRoe @MergencyFe @andreaskardio @Moeritzl Na ja die Daten bei AHRE sind halt eher gegen eine antikoagulation oder? https://t.co/jTdH7XFM5S
@ecgandrhythmRoe @WeyandSebastian ich auch und zwar sofort, ohne EKG-Bestätigung aber diese Studie sagt klares Nein https://t.co/r6WTiH0U8S
RT @Method_Focused: 今週の #メソッドジャーナルクラブ は、心房高頻拍エピソードの発生を基準に抗凝固薬治療を開始するのは有用か調べた研究を扱いました。 主解析には原因別Cox比例ハザードモデルを用いています。 Anticoagulation with Edo…
@FGProcopio @CONAREC_ORG @SIAC_cardio @ComunidadFAC @clinicasac Si sumamos a tu
RT @Method_Focused: 今週の #メソッドジャーナルクラブ は、心房高頻拍エピソードの発生を基準に抗凝固薬治療を開始するのは有用か調べた研究を扱いました。 主解析には原因別Cox比例ハザードモデルを用いています。 Anticoagulation with Edo…
今週の #メソッドジャーナルクラブ は、心房高頻拍エピソードの発生を基準に抗凝固薬治療を開始するのは有用か調べた研究を扱いました。 主解析には原因別Cox比例ハザードモデルを用いています。 Anticoagulation with Edoxaban in Patients with Atrial High-Rate Episodes https://t.co/lVRPXzN2fI
@stephen_t_webb but increases major bleeding... And then you look at this which also used a >6 min cutoff for AHREs and there was no benefit (NOAH AFNET 6 trial) https://t.co/TnFhm8OMLY Such a challenging area of practice...
Also with NOAH-AFNET https://t.co/UbOjTFxcwZ in patients with atrial high rate episodes (which could be like Epi-phenomena for atrial fibrillation) no difference in cardioembolic events when edoxaban was used for primary prevention and higher risk of bleeding. https://t.co/aTYgbqRbZI
Anticoagulation with Edoxaban in Patients with Atrial High-Rate Episodes | NEJM https://t.co/7BTRIK35cS
3/ Patients with device-detected atrial high rate episodes do not benefit from anticoagulation. https://t.co/3NgChVn90H
#EHRAtopicweek NOAH-AFNET6 No reduction of the incidence of the composite outcome (CV death, stroke, systemic embolism), but higher risk of death or major bleeding Have a look ! https://t.co/89ju3vrW9u
RT @kaulcsmc: Reconciling favorable results in ARTESIA with neutral or harmful results in NOAH-AFNET 6 (edoxaban vs placebo) is challenging…
RT @kaulcsmc: Reconciling favorable results in ARTESIA with neutral or harmful results in NOAH-AFNET 6 (edoxaban vs placebo) is challenging…
@arvsinghal https://t.co/TtvuzdwQNZ
@arvsinghal Subclinical AF is different to persistent AF The NOAH study was Edoxaban against placebo and placebo won Unless SCAF is >24 hours on devices, we don’t have a mandate to anticoagulate DOI: 10.1056/NEJMoa2303062
Guardadas las diferencias entre los estudios, está era la evidencia reciente que teníamos. ¿La población? ¿La intervención? #AHA23 https://t.co/6XX5Kjm8zc
Reconciling favorable results in ARTESIA with neutral or harmful results in NOAH-AFNET 6 (edoxaban vs placebo) is challenging! https://t.co/wJjM2Apzp2 High Rx discontinuation rate: 58-59% (24% for AF>24h) PEP (OT analysis): 0.71 vs 1.29% /PY, HR 0.55, 0.37-0.83
RT @SABOURETCardio: Anticoagulation with #Edoxaban in Patients with #AF Atrial High-Rate Episodes. #AHA23 #DOAC https://t.co/OsTfyOpYpN
RT @SABOURETCardio: Anticoagulation with #Edoxaban in Patients with #AF Atrial High-Rate Episodes. #AHA23 #DOAC https://t.co/OsTfyOpYpN
RT @SABOURETCardio: Anticoagulation with #Edoxaban in Patients with #AF Atrial High-Rate Episodes. #AHA23 #DOAC https://t.co/OsTfyOpYpN
RT @SABOURETCardio: Anticoagulation with #Edoxaban in Patients with #AF Atrial High-Rate Episodes. #AHA23 #DOAC https://t.co/OsTfyOpYpN
RT @SABOURETCardio: Anticoagulation with #Edoxaban in Patients with #AF Atrial High-Rate Episodes. #AHA23 #DOAC https://t.co/OsTfyOpYpN
RT @SABOURETCardio: Anticoagulation with #Edoxaban in Patients with #AF Atrial High-Rate Episodes. #AHA23 #DOAC https://t.co/OsTfyOpYpN
RT @SABOURETCardio: Anticoagulation with #Edoxaban in Patients with #AF Atrial High-Rate Episodes. #AHA23 #DOAC https://t.co/OsTfyOpYpN
RT @SABOURETCardio: Anticoagulation with #Edoxaban in Patients with #AF Atrial High-Rate Episodes. #AHA23 #DOAC https://t.co/OsTfyOpYpN
Anticoagulation with #Edoxaban in Patients with #AF Atrial High-Rate Episodes. #AHA23 #DOAC https://t.co/OsTfyOpYpN
@V_Mardigyan NOAH-AFNET was not very encouraging! Trial terminated early for futility Death or bleeding worse on edoxaban. https://t.co/wJjM2Apzp2
RT @venkmurthy: For years, I raised concern treating AFib detected by watches may not avert stroke/save lives. RCT out now shows anticoag…
RT @venkmurthy: For years, I raised concern treating AFib detected by watches may not avert stroke/save lives. RCT out now shows anticoag…
RT @alejandroipc2: NOAH-AFNET 6 Edoxabán no muestra beneficio en pacientes con AHRE y se asocia a una mayor incidencia de muerte o sangra…
RT @cardio_tu: 2 min cardiology（臨床論文、担当：伊藤知宏） Anticoagulation with Edoxaban in Patients with Atrial High-Rate Episodes. P. Kirchhof, et…
2 min cardiology（臨床論文、担当：伊藤知宏） Anticoagulation with Edoxaban in Patients with Atrial High-Rate Episodes. P. Kirchhof, et al. N Engl J Med 2023; 389:1167-1179
https://t.co/yQepAGExa1
RT @2Scottish: Anticoagulation with Edoxaban in Patients with Atrial High-Rate Episodes — no Benefit. https://t.co/i1dJrC6sCI https://t.co…
RT @2Scottish: Anticoagulation with Edoxaban in Patients with Atrial High-Rate Episodes — no Benefit. https://t.co/i1dJrC6sCI https://t.co…
RT @2Scottish: Anticoagulation with Edoxaban in Patients with Atrial High-Rate Episodes — no Benefit. https://t.co/i1dJrC6sCI https://t.co…
RT @2Scottish: Anticoagulation with Edoxaban in Patients with Atrial High-Rate Episodes — no Benefit. https://t.co/i1dJrC6sCI https://t.co…
RT @2Scottish: Anticoagulation with Edoxaban in Patients with Atrial High-Rate Episodes — no Benefit. https://t.co/i1dJrC6sCI https://t.co…
Anticoagulation with Edoxaban in Patients with Atrial High-Rate Episodes — no Benefit. https://t.co/i1dJrC6sCI https://t.co/DriPoM7JVJ
#Anticoagulation with Edoxaban in Patients with Atrial High-Rate Episodes For More: https://t.co/vqDE02Tc4c
RT @NEJM: Read the full results of the NOAH-AFNET 6 trial, presented today at #ESCCongress: Original Article: Anticoagulation with Edoxaba…
RT @DrMarkMills: Another stimulating @LHCH Electrophysiology Journal Club this week: CASTLE -HTx RCT: https://t.co/uoi22zQefp Anticoagula…
RT @RevistaMFSamfyc: Anticoagulación con edoxaban en pacientes con episodios de taquicardia auricular https://t.co/ywBV4byi48 PMID 37622677
Will results of ARTESiA and published results of NOAH-AF have any sway on anticoagulation decisions for SCAF in the cancer population (active cancer was not a C.I. to enrolment in either trial, although % patients with cancer not reported). https://t.co/nzIR8NAZ7O
Another stimulating @LHCH Electrophysiology Journal Club this week: CASTLE -HTx RCT: https://t.co/uoi22zQefp Anticoagulation in patients with AHRE: https://t.co/tGEN5NB1a8 ADVENT RCT: https://t.co/mdZ8snKsQf Insights from DECAAF II on blanking period: https://t.co/DZEklHa4wH
RT @LuisZuritaG: Anticoagulación con edoxabán en pacientes con episodios de alta tasa auricular | NEJM https://t.co/P8UzYnPTTd
RT @LuisZuritaG: Anticoagulación con edoxabán en pacientes con episodios de alta tasa auricular | NEJM https://t.co/P8UzYnPTTd
Anticoagulación con edoxabán en pacientes con episodios de alta tasa auricular | NEJM https://t.co/P8UzYnPTTd
Anticoagulation w Edoxaban in Pts w Atrial High-Rate Episodes: didn't significantly reduce incidence of composite of cardiovascular death, stroke, or systemic embolism vs placebo, but higher incidence of a composite of death or major bleeding https://t.co/eomve5yBrs
La anticoagulación con edoxabán en pacientes con episodios auriculares de frecuencia alta detectados por dispositivo no redujo la incidencia de una combinación de muerte cardiovascular, accidente cerebrovascular o embolia sistémica respecto placebo,... https://t.co/ri7Clv9Ou0
WE ARE FINALLY GETTING FREE OF JUST CHADS2VASC FOR SUBCLIICAL AFIB Anticoagulation with Edoxaban in Patients with Atrial High-Rate Episodes | NEJM https://t.co/MlSAqqwIbU
Anticoagulación con edoxaban en pacientes con episodios de taquicardia auricular https://t.co/ywBV4byi48 PMID 37622677
Anticoagulation with Edoxaban in Patients with Atrial High-Rate Episodes
RT @CulebrasCruz:
・65歳以上でatrial high rate episodeがあった人にエドキサバンを飲ませたRCT ・一次評価は心血管死、脳卒中、全身性塞栓症の複合アウトカム ・結果はHR0.81 (95%CI 0.60-1.08) ・全死亡とmajor bleedingがエドキサバン群で有意に多くHR1.31(95%CI 1.02-1.67 ) https://t.co/gPPw8tDFoj
https://t.co/jC6hGJYyJd AHREsの患者におけるエドキサバンの使用に関する臨床試験結果：エドキサバンは、心血管死、脳卒中、全身塞栓症の複合アウトカムを有意に減少させない、死亡率と大出血率が高い。脳卒中の発生率は低い。
In patients with AHREs, edoxaban did not significantly reduce the incidence of a composite primary efficacy outcome as compared with placebo, but it led to a higher incidence of a composite primary safety outcome https://t.co/ZKoRx41RJX #visualabstract #dataviz https://t.co/SN2DJeSE1A
Anticoagulation with Edoxaban in Patients with Atrial High-Rate Episodes anticoagulation with edoxaban did not significantly reduce the incidence of a composite of cardiovascular death, stroke, or systemic embolism as compared with placebo, https://t.co/6pLq40NAiW
RT @jvillacastin: Tienes un paciente de 80 años con marcapasos. De repente encuentras una racha de fibrilación auricular en la revisión, de…
RT @AshuPJadhav: Anticoagulation with Edoxaban in Patients with Atrial High-Rate Episodes | NEJM https://t.co/1oYkAuvwMX https://t.co/mGp1U…
RT @NEJM: Oral anticoagulants reduce the risk of stroke in patients with atrial fibrillation. Implantable cardiac devices can detect subcli…
RT @NEJM: Oral anticoagulants reduce the risk of stroke in patients with atrial fibrillation. Implantable cardiac devices can detect subcli…
RT @NEJM: Oral anticoagulants reduce the risk of stroke in patients with atrial fibrillation. Implantable cardiac devices can detect subcli…
RT @NEJM: Oral anticoagulants reduce the risk of stroke in patients with atrial fibrillation. Implantable cardiac devices can detect subcli…
RT @NEJM: Oral anticoagulants reduce the risk of stroke in patients with atrial fibrillation. Implantable cardiac devices can detect subcli…
RT @NEJM: Oral anticoagulants reduce the risk of stroke in patients with atrial fibrillation. Implantable cardiac devices can detect subcli…
RT @NEJM: Oral anticoagulants reduce the risk of stroke in patients with atrial fibrillation. Implantable cardiac devices can detect subcli…
RT @NEJM: Oral anticoagulants reduce the risk of stroke in patients with atrial fibrillation. Implantable cardiac devices can detect subcli…
RT @NEJM: Oral anticoagulants reduce the risk of stroke in patients with atrial fibrillation. Implantable cardiac devices can detect subcli…
RT @NEJM: Oral anticoagulants reduce the risk of stroke in patients with atrial fibrillation. Implantable cardiac devices can detect subcli…
RT @NEJM: Oral anticoagulants reduce the risk of stroke in patients with atrial fibrillation. Implantable cardiac devices can detect subcli…
RT @NEJM: Oral anticoagulants reduce the risk of stroke in patients with atrial fibrillation. Implantable cardiac devices can detect subcli…
RT @NEJM: Oral anticoagulants reduce the risk of stroke in patients with atrial fibrillation. Implantable cardiac devices can detect subcli…
RT @AshuPJadhav: Anticoagulation with Edoxaban in Patients with Atrial High-Rate Episodes | NEJM https://t.co/1oYkAuvwMX https://t.co/mGp1U…
RT @NEJM: Oral anticoagulants reduce the risk of stroke in patients with atrial fibrillation. Implantable cardiac devices can detect subcli…
RT @NEJM: Oral anticoagulants reduce the risk of stroke in patients with atrial fibrillation. Implantable cardiac devices can detect subcli…
RT @NEJM: Oral anticoagulants reduce the risk of stroke in patients with atrial fibrillation. Implantable cardiac devices can detect subcli…
RT @AshuPJadhav: Anticoagulation with Edoxaban in Patients with Atrial High-Rate Episodes | NEJM https://t.co/1oYkAuvwMX https://t.co/mGp1U…
RT @NEJM: Oral anticoagulants reduce the risk of stroke in patients with atrial fibrillation. Implantable cardiac devices can detect subcli…
RT @NEJM: Oral anticoagulants reduce the risk of stroke in patients with atrial fibrillation. Implantable cardiac devices can detect subcli…
RT @NEJM: Oral anticoagulants reduce the risk of stroke in patients with atrial fibrillation. Implantable cardiac devices can detect subcli…
RT @NEJM: Oral anticoagulants reduce the risk of stroke in patients with atrial fibrillation. Implantable cardiac devices can detect subcli…
RT @NEJM: Oral anticoagulants reduce the risk of stroke in patients with atrial fibrillation. Implantable cardiac devices can detect subcli…
Anticoagulation with Edoxaban in Patients with Atrial High-Rate Episodes | NEJM https://t.co/1oYkAuvwMX https://t.co/mGp1URNUab
RT @NEJM: Oral anticoagulants reduce the risk of stroke in patients with atrial fibrillation. Implantable cardiac devices can detect subcli…
Oral anticoagulants reduce the risk of stroke in patients with atrial fibrillation. Implantable cardiac devices can detect subclinical atrial high-rate episodes in patients without #AFib. Full NOAH-AFNET 6 trial Research Summary: https://t.co/e45Il0OeG2 #AFibAwarenessMonth
Only anticoagulate actual atrial fib episodes https://t.co/oa0ulry8mQ
https://t.co/PDCoRW8Qnr
RT @jvillacastin: Tienes un paciente de 80 años con marcapasos. De repente encuentras una racha de fibrilación auricular en la revisión, de…
Anticoagulation with Edoxaban in Patients with Atrial High-Rate Episodes https://t.co/8Fjvi4Pmhc
RT @jvillacastin: Tienes un paciente de 80 años con marcapasos. De repente encuentras una racha de fibrilación auricular en la revisión, de…
Edoxaban did not reduce risk of cardiovascular death, stroke, or systemic embolism among patients with atrial high-rate episodes (AHRE) detected by implanted devices and no history of atrial fibrillation on ECG https://t.co/ylIxXO9unu https://t.co/zWl1TOZjKj
RT @afnet_ev: ▶️Is #anticoagulation effective and safe in patients with #AHRE? Check out the much-needed data of our #NOAHtrial - print ver…
RT @jvillacastin: Tienes un paciente de 80 años con marcapasos. De repente encuentras una racha de fibrilación auricular en la revisión, de…
RT @jvillacastin: Tienes un paciente de 80 años con marcapasos. De repente encuentras una racha de fibrilación auricular en la revisión, de…
RT @jvillacastin: Tienes un paciente de 80 años con marcapasos. De repente encuentras una racha de fibrilación auricular en la revisión, de…
Tienes un paciente de 80 años con marcapasos. De repente encuentras una racha de fibrilación auricular en la revisión, de 15 minutos de duración. Anticoagulantes? Anticoagulation with Edoxaban in Patients with Atrial High-Rate Episodes | NEJM https://t.co/tL0Y0sm7gR
Finally the print version: Must read!!! Should patients with AHREs get anticoagulation? https://t.co/i4BZZKlRxn
▶️Is #anticoagulation effective and safe in patients with #AHRE? Check out the much-needed data of our #NOAHtrial - print version released today in NEJM! https://t.co/Dh8jrZh7m8 @UKEHamburg #Afib #AFNET https://t.co/ZnTZeYIWTF
RT @NEJM: Original Article: Anticoagulation with Edoxaban in Patients with Atrial High-Rate Episodes (NOAH-AFNET 6 trial) https://t.co/e45I…
Anticoagulation with Edoxaban in Patients with Atrial High-Rate Episodes | NEJM FA de alto ritmo (>170lpm por al menos 6min o más) No disminuyó riesgo de stroke https://t.co/9kwA4ZwHhR
RT @NEJM: Original Article: Anticoagulation with Edoxaban in Patients with Atrial High-Rate Episodes (NOAH-AFNET 6 trial) https://t.co/e45I…
RT @NEJM: Original Article: Anticoagulation with Edoxaban in Patients with Atrial High-Rate Episodes (NOAH-AFNET 6 trial) https://t.co/e45I…
RT @NEJM: Original Article: Anticoagulation with Edoxaban in Patients with Atrial High-Rate Episodes (NOAH-AFNET 6 trial) https://t.co/e45I…
RT @NEJM: Original Article: Anticoagulation with Edoxaban in Patients with Atrial High-Rate Episodes (NOAH-AFNET 6 trial) https://t.co/e45I…
RT @NEJM: Original Article: Anticoagulation with Edoxaban in Patients with Atrial High-Rate Episodes (NOAH-AFNET 6 trial) https://t.co/e45I…
RT @NEJM: Original Article: Anticoagulation with Edoxaban in Patients with Atrial High-Rate Episodes (NOAH-AFNET 6 trial) https://t.co/e45I…
Original Article: Anticoagulation with Edoxaban in Patients with Atrial High-Rate Episodes (NOAH-AFNET 6 trial) https://t.co/e45Il0OeG2 Editorial: Harnessing the Deluge of Rhythm-Monitoring Data for the Prevention of Stroke https://t.co/MspuxG7c40 https://t.co/ioe6wI3jWJ
RT @EARL_med_tw:
RT @2minmed: #VisualAbstract: Anticoagulation with Edoxaban in Patients with Atrial High-Rate Episodes #StudyGraphics #anticoagulation htt…
RT @EARL_med_tw:
RT @EARL_med_tw:
#VisualAbstract: Anticoagulation with Edoxaban in Patients with Atrial High-Rate Episodes #StudyGraphics #anticoagulation https://t.co/BOPA8NOr0p https://t.co/YAiYr2KpnS
RT @keisuke4713: 心房性高頻度episode 抗凝固療法Edoxaban https://t.co/utM5k05lxE 心血管死、脳卒中、全身性塞栓 プラセボ群101人4％/患者・年 Edoxaban群83人3.2％/患者・年で有意差無し 脳卒中：両群とも約…
心房性高頻度episode 抗凝固療法Edoxaban https://t.co/utM5k05lxE 心血管死、脳卒中、全身性塞栓 プラセボ群101人4％/患者・年 Edoxaban群83人3.2％/患者・年で有意差無し 脳卒中：両群とも約1％/患者・年 全死亡か重篤な出血 プラセボ群114人4.5％/患者・年 Edoxaban群149人5.9％/患者・年と有意⬆️
RT @NEJM: Read the full results of the NOAH-AFNET 6 trial, presented today at #ESCCongress: Original Article: Anticoagulation with Edoxaba…
RT @NEJM: Original Article: Anticoagulation with Edoxaban in Patients with Atrial High-Rate Episodes (NOAH-AFNET 6 trial) https://t.co/e45I…
RT @atmizu: 【俺のESC①】 昨年と同様で 末永先生とのピックアップHOTLINEです~ 是非是非どうぞ～ m3さんの会員は無料です
【俺のESC①】 昨年と同様で 末永先生とのピックアップHOTLINEです~ 是非是非どうぞ～ m3さんの会員は無料です
RT @NEJM: Original Article: Anticoagulation with Edoxaban in Patients with Atrial High-Rate Episodes (NOAH-AFNET 6 trial) https://t.co/e45I…
Anticoagulation with Edoxaban in Patients with Atrial High-Rate Episodes | NEJM https://t.co/5rJXR1YwdM
Anticoagulation With Edoxaban in Patients With Atrial High-Rate Episodes https://t.co/aZRTdksseg @practiceupdateより
【RCT】65歳以上、1つ以上の脳卒中の追加のリスク因子をもつ6分以上の心房性頻拍イベントがある患者へのエドキサバン投与は、プラセボ投与と比較して、心血管死亡、脳卒中、全身性塞栓症を減少させなかった。 #ペ読 https://t.co/HpfPbThFL0
RT @NEJM: Original Article: Anticoagulation with Edoxaban in Patients with Atrial High-Rate Episodes (NOAH-AFNET 6 trial) https://t.co/e45I…
RT @juanjolopezn: Anticoagulation with Edoxaban in Patients with Atrial High-Rate Episodes @NEJM https://t.co/swUGhbvv35
RT @NEJM: Original Article: Anticoagulation with Edoxaban in Patients with Atrial High-Rate Episodes (NOAH-AFNET 6 trial) https://t.co/e45I…
Hold the Anticoagulants!! Anticoagulation with Edoxaban in Patients with Atrial High-Rate Episodes | NEJM https://t.co/PnJ9QRObzk
RT @NEJM: Original Article: Anticoagulation with Edoxaban in Patients with Atrial High-Rate Episodes (NOAH-AFNET 6 trial) https://t.co/e45I…
Non-vitamin K antagonist oral anticoagulants in patients with atrial high rate episodes Results of the NOAH study published in @NEJM #ISRCTN: https://t.co/YXH42oMSwD https://t.co/aSkv1RQX5L
Anticoagulation with Edoxaban in Patients with Atrial High-Rate Episodes | NEJM https://t.co/zxGAzeLxyc
Anticoagulation with Edoxaban in Patients with Atrial High-Rate Episodes @NEJM https://t.co/swUGhbvv35
RT @NEJM: Original Article: Anticoagulation with Edoxaban in Patients with Atrial High-Rate Episodes (NOAH-AFNET 6 trial) https://t.co/e45I…
RT @NEJM: Original Article: Anticoagulation with Edoxaban in Patients with Atrial High-Rate Episodes (NOAH-AFNET 6 trial) https://t.co/e45I…
RT @NEJM: Original Article: Anticoagulation with Edoxaban in Patients with Atrial High-Rate Episodes (NOAH-AFNET 6 trial) https://t.co/e45I…
RT @NEJM: Original Article: Anticoagulation with Edoxaban in Patients with Atrial High-Rate Episodes (NOAH-AFNET 6 trial) https://t.co/e45I…
RT @NEJM: Original Article: Anticoagulation with Edoxaban in Patients with Atrial High-Rate Episodes (NOAH-AFNET 6 trial) https://t.co/e45I…
RT @NEJM: Original Article: Anticoagulation with Edoxaban in Patients with Atrial High-Rate Episodes (NOAH-AFNET 6 trial) https://t.co/e45I…
RT @NEJM: Original Article: Anticoagulation with Edoxaban in Patients with Atrial High-Rate Episodes (NOAH-AFNET 6 trial) https://t.co/e45I…
RT @NEJM: Original Article: Anticoagulation with Edoxaban in Patients with Atrial High-Rate Episodes (NOAH-AFNET 6 trial) https://t.co/e45I…
RT @NEJM: Original Article: Anticoagulation with Edoxaban in Patients with Atrial High-Rate Episodes (NOAH-AFNET 6 trial) https://t.co/e45I…
RT @NEJM: Original Article: Anticoagulation with Edoxaban in Patients with Atrial High-Rate Episodes (NOAH-AFNET 6 trial) https://t.co/e45I…
RT @NEJM: Original Article: Anticoagulation with Edoxaban in Patients with Atrial High-Rate Episodes (NOAH-AFNET 6 trial) https://t.co/e45I…
RT @NEJM: Original Article: Anticoagulation with Edoxaban in Patients with Atrial High-Rate Episodes (NOAH-AFNET 6 trial) https://t.co/e45I…
RT @NEJM: Original Article: Anticoagulation with Edoxaban in Patients with Atrial High-Rate Episodes (NOAH-AFNET 6 trial) https://t.co/e45I…
RT @NEJM: Original Article: Anticoagulation with Edoxaban in Patients with Atrial High-Rate Episodes (NOAH-AFNET 6 trial) https://t.co/e45I…
RT @NEJM: Original Article: Anticoagulation with Edoxaban in Patients with Atrial High-Rate Episodes (NOAH-AFNET 6 trial) https://t.co/e45I…
RT @NEJM: Original Article: Anticoagulation with Edoxaban in Patients with Atrial High-Rate Episodes (NOAH-AFNET 6 trial) https://t.co/e45I…
RT @NEJM: Original Article: Anticoagulation with Edoxaban in Patients with Atrial High-Rate Episodes (NOAH-AFNET 6 trial) https://t.co/e45I…
RT @JuanGrvas: ¿Edoxaban (Lixiana) para prevenir ictus en caso de fibrilación auricular sin clínica? No disminuye los ictus, aumenta las…
RT @NEJM: Original Article: Anticoagulation with Edoxaban in Patients with Atrial High-Rate Episodes (NOAH-AFNET 6 trial) https://t.co/e45I…
RT @NEJM: Original Article: Anticoagulation with Edoxaban in Patients with Atrial High-Rate Episodes (NOAH-AFNET 6 trial) https://t.co/e45I…
RT @NEJM: Original Article: Anticoagulation with Edoxaban in Patients with Atrial High-Rate Episodes (NOAH-AFNET 6 trial) https://t.co/e45I…
RT @NEJM: Original Article: Anticoagulation with Edoxaban in Patients with Atrial High-Rate Episodes (NOAH-AFNET 6 trial) https://t.co/e45I…
RT @NEJM: Original Article: Anticoagulation with Edoxaban in Patients with Atrial High-Rate Episodes (NOAH-AFNET 6 trial) https://t.co/e45I…
RT @NEJM: Original Article: Anticoagulation with Edoxaban in Patients with Atrial High-Rate Episodes (NOAH-AFNET 6 trial) https://t.co/e45I…
RT @NEJM: Original Article: Anticoagulation with Edoxaban in Patients with Atrial High-Rate Episodes (NOAH-AFNET 6 trial) https://t.co/e45I…
RT @NEJM: Original Article: Anticoagulation with Edoxaban in Patients with Atrial High-Rate Episodes (NOAH-AFNET 6 trial) https://t.co/e45I…
RT @NEJM: Original Article: Anticoagulation with Edoxaban in Patients with Atrial High-Rate Episodes (NOAH-AFNET 6 trial) https://t.co/e45I…
Anticoagulation with Edoxaban in Patients with Atrial High-Rate Episodes | NEJM https://t.co/oGliwY8ecp
RT @NEJM: Original Article: Anticoagulation with Edoxaban in Patients with Atrial High-Rate Episodes (NOAH-AFNET 6 trial) https://t.co/e45I…
RT @NEJM: Original Article: Anticoagulation with Edoxaban in Patients with Atrial High-Rate Episodes (NOAH-AFNET 6 trial) https://t.co/e45I…
RT @NEJM: Original Article: Anticoagulation with Edoxaban in Patients with Atrial High-Rate Episodes (NOAH-AFNET 6 trial) https://t.co/e45I…
RT @NEJM: Original Article: Anticoagulation with Edoxaban in Patients with Atrial High-Rate Episodes (NOAH-AFNET 6 trial) https://t.co/e45I…
RT @NEJM: Original Article: Anticoagulation with Edoxaban in Patients with Atrial High-Rate Episodes (NOAH-AFNET 6 trial) https://t.co/e45I…
RT @NEJM: Original Article: Anticoagulation with Edoxaban in Patients with Atrial High-Rate Episodes (NOAH-AFNET 6 trial) https://t.co/e45I…
¿Edoxaban (Lixiana) para prevenir ictus en caso de fibrilación auricular sin clínica? No disminuye los ictus, aumenta las hemorragias y las muertes. Avoid anticoagulation with edoxaban in patients with atrial high-rate episodes. https://t.co/wtgXvIMvqK https://t.co/bf4d0Wc0M1
RT @NEJM: Original Article: Anticoagulation with Edoxaban in Patients with Atrial High-Rate Episodes (NOAH-AFNET 6 trial) https://t.co/e45I…
RT @NEJM: Original Article: Anticoagulation with Edoxaban in Patients with Atrial High-Rate Episodes (NOAH-AFNET 6 trial) https://t.co/e45I…
RT @NEJM: Original Article: Anticoagulation with Edoxaban in Patients with Atrial High-Rate Episodes (NOAH-AFNET 6 trial) https://t.co/e45I…
RT @NEJM: Original Article: Anticoagulation with Edoxaban in Patients with Atrial High-Rate Episodes (NOAH-AFNET 6 trial) https://t.co/e45I…
デバイスで偶発的に検出された心房性頻拍に対する「エドキサバン」（RCT、n=2,536、平均78歳）。 ・心血管死/脳卒中/全身塞栓症の複合：HR=0.81 [0.60-1.08] ・全死因死亡/大出血：HR=1.31 [1.02-1.67] N Engl J Med . 2023 Aug 25. Online ahead of print. PMID:37622677 https://t.co/AaH20B9IhE
No Effect of anticoagulation for AHRE at NEJM. What a result! A cut off needed for AHRE to predict Stroke Anticoagulation with Edoxaban in Patients with Atrial High-Rate Episodes - PubMed https://t.co/1OLYggVgtW